Methods of treating skin disorders with caffeic acid analogs

Abstract

Embodiments of the invention generally relate to pharmaceutical compositions containing at least one caffeic acid compound and methods for the topical treatment of proliferative and inflammatory skin disorders such as plaque psoriasis, atopic dermatitis, and other disorders. In some embodiments, the topical treatment includes applications of the pharmaceutical composition containing at least one caffeic acid compound or a mixture of caffeic acid compounds such as caffeic acid ester compounds, caffeic acid amide compounds, analogues thereof, derivatives thereof, salts thereof, or mixtures thereof. The pharmaceutical composition or topical dosage may contain the caffeic acid compound at a concentration by weight within a range from about 0.01% to about 20%, preferably, from about 0.1% to about 15%, preferably, from about 1% to about 10%, more preferably, from about 3% to about 7%, and more preferably, from about 4% to about 6%.

What is claimed is: 
     
         1 . A method for treating proliferative skin disorders, comprising applying a topical pharmaceutical composition to a lesion, wherein the topical pharmaceutical composition comprises a compound of Formula I: 
       
         
           
           
               
               
           
         
       
       wherein:
 X is a halogen; 
 R is selected from the group consisting of hydrogen, hydroxyl, alkyl, alkoxy, C 3 -C 7 -cycloalkyl, C 6 -C 10 -aryl, and 
 the topical pharmaceutical composition comprises the compound of Formula I at a concentration by weight within a range from about 0.01% to about 20%. 
 
     
     
         2 . The method of  claim 1 , wherein the topical pharmaceutical composition comprises the compound of  claim 1  at a concentration by weight within a range from about 1% to about 10%. 
     
     
         3 . The method of  claim 2 , wherein the topical pharmaceutical composition comprises the compound of  claim 1  at a concentration by weight within a range from about 3% to about 7%. 
     
     
         4 . The method of  claim 1 , wherein the compound of  claim 1  has the chemical structure of: 
       
         
           
           
               
               
           
         
       
     
     
         5 . The method of  claim 1 , wherein the compound of  claim 1  has the chemical structure of: 
       
         
           
           
               
               
           
         
       
     
     
         6 . The method of  claim 1 , wherein the compound of  claim 1  has the chemical structure of: 
       
         
           
           
               
               
           
         
       
     
     
         7 . The method of  claim 1 , wherein the topical pharmaceutical composition further comprises at least one additional agent selected from the group consisting of cell differentiating agents, anti-proliferative agents, mitochondrial inhibitors, topical steroids, immunosuppressive compounds, JAK2 inhibitors, JAK3 inhibitors, parathyroid hormone-related protein (PTHrP) agonists, cell adhesion blockers, and combinations thereof. 
     
     
         8 . The method of  claim 1 , wherein the topical pharmaceutical composition further comprises a cell differentiating agent selected from the group consisting of retinoic acid, retinoic acid derivative, vitamin D, and a vitamin D analog. 
     
     
         9 . The method of  claim 1 , wherein the topical pharmaceutical composition is applied multiple times daily until symptoms of the disorder disappear. 
     
     
         10 . A method for treating proliferative skin disorders, comprising applying a topical pharmaceutical composition to a lesion, wherein the topical pharmaceutical composition comprises a compound having the chemical structure: 
       
         
           
           
               
               
           
         
       
       at a concentration by weight within a range from about 0.01% to about 20%. 
     
     
         11 . The method of  claim 10 , wherein the topical pharmaceutical composition comprises the compound of  claim 10  at a concentration by weight within a range from about 1% to about 10%. 
     
     
         12 . The method of  claim 11 , wherein the topical pharmaceutical composition comprises the compound of  claim 10  at a concentration by weight within a range from about 3% to about 7%. 
     
     
         13 . The method of  claim 10 , wherein the topical pharmaceutical composition further comprises at least one additional agent selected from the group consisting of cell differentiating agents, anti-proliferative agents, mitochondrial inhibitors, topical steroids, immunosuppressive compounds, JAK2 inhibitors, JAK3 inhibitors, parathyroid hormone-related protein (PTHrP) agonists, cell adhesion blockers, and combinations thereof. 
     
     
         14 . The method of  claim 10 , wherein the topical pharmaceutical composition further comprises a cell differentiating agent selected from the group consisting of retinoic acid, retinoic acid derivative, vitamin D, or and a vitamin D analog. 
     
     
         15 . The method of  claim 10 , wherein the topical pharmaceutical composition is applied multiple times daily until symptoms of the disorder disappear. 
     
     
         16 - 26 . (canceled)